Related Experiment Video

Updated: Aug 21, 2026

Reduction in Left Ventricular Wall Stress and Improvement in Function in Failing Hearts using Algisyl-LVR
07:24

Reduction in Left Ventricular Wall Stress and Improvement in Function in Failing Hearts using Algisyl-LVR

Published on: April 8, 2013

Effect of atorvastatin on left ventricular diastolic function and ability of coenzyme Q10 to reverse that dysfunction

Marc A Silver1, Peter H Langsjoen, Szabolcs Szabo

  • 1Heart Failure Institute, Department of Medicine, Advocate Christ Medical Center, University of Illinois/Christ Cardiovascular Disease Fellowship Program, Oak Lawn, Illinois 60453, USA. marc.silver@advocatehealth.com <marc.silver@advocatehealth.com>

The American Journal of Cardiology
|November 16, 2004
PubMed

Insights

Statin therapy can negatively impact heart diastolic function. However, coenzyme Q(10) supplementation may help improve these diastolic parameters in patients experiencing statin-related changes.

Area of Science:

  • Cardiology
  • Pharmacology
  • Biochemistry

Background:

  • Statin medications are widely prescribed for cardiovascular disease prevention.
  • Potential adverse effects of statins on cardiac function require thorough investigation.

Purpose of the Study:

  • To assess the impact of statin therapy on left ventricular diastolic function.
  • To evaluate the efficacy of coenzyme Q(10) supplementation in mitigating statin-induced diastolic dysfunction.

Main Methods:

  • Doppler echocardiography was utilized to measure diastolic parameters.
  • Measurements were taken before and after the initiation of statin therapy.
  • Coenzyme Q(10) was administered to a subset of patients experiencing worsened diastolic function.

Main Results:

  • Statin therapy was associated with a decline in diastolic function parameters in the majority of patients.
  • Coenzyme Q(10) supplementation led to significant improvements in diastolic function parameters.
  • Patients receiving coenzyme Q(10) showed reversal of statin-associated diastolic impairments.

Conclusions:

  • Statin therapy may adversely affect left ventricular diastolic function.
  • Coenzyme Q(10) supplementation presents a potential therapeutic strategy to counteract statin-induced diastolic dysfunction.
  • Further research is warranted to elucidate the mechanisms and long-term effects.

Related Concept Videos

Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
Coronary Artery Disease II: Pathophysiology01:26

Coronary Artery Disease II: Pathophysiology

Coronary Artery Disease (CAD) originates from a series of events that impair the function of coronary arteries, the blood vessels responsible for delivering oxygen-rich blood to the heart muscle. The pathophysiology of CAD is closely linked to atherosclerosis, a chronic inflammatory and lipid-driven condition affecting the vascular endothelium.1. Endothelial DamageThe process begins with damage to the vascular endothelium, which serves as a protective barrier between the blood and the vessel...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Heart Failure Drugs: &#946;-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...